258 related articles for article (PubMed ID: 11447300)
1. Therapeutic role of bosentan in hypertension: lessons from the model of perinephritic hypertension.
Donckier JE
Heart Fail Rev; 2001 Dec; 6(4):253-64. PubMed ID: 11447300
[TBL] [Abstract][Full Text] [Related]
2. Endothelin and endothelin antagonists in hypertension.
Schiffrin EL
J Hypertens; 1998 Dec; 16(12 Pt 2):1891-5. PubMed ID: 9886874
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page hypertension.
Massart PE; Hodeige DG; Van Mechelen H; Charlier AA; Ketelslegers JM; Heyndrickx GR; Donckier JE
J Hypertens; 1998 Jun; 16(6):835-41. PubMed ID: 9663924
[TBL] [Abstract][Full Text] [Related]
4. Endothelin-1 receptor antagonism does not influence myocardial function in hypertensive dogs.
Massart PE; Hodeige D; Van Mechelen H; Heyndrickx GR; Donckier J
Eur J Clin Invest; 1998 Oct; 28(10):798-806. PubMed ID: 9792992
[TBL] [Abstract][Full Text] [Related]
5. Role of endothelin in the control of peripheral vascular tone in human hypertension.
Taddei S; Virdis A; Ghiadoni L; Sudano I; Magagna A; Salvetti A
Heart Fail Rev; 2001 Dec; 6(4):277-85. PubMed ID: 11447302
[TBL] [Abstract][Full Text] [Related]
6. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition.
Donckier JE; Massart PE; Hodeige D; Van Mechelen H; Clozel JP; Laloux O; Ketelslegers JM; Charlier AA; Heyndrickx GR
Circulation; 1997 Aug; 96(4):1250-6. PubMed ID: 9286956
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic effects of bosentan in patients with chronic heart failure.
Kiowski W; Sütsch G; Oechslin E; Bertel O
Heart Fail Rev; 2001 Dec; 6(4):325-34. PubMed ID: 11447307
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II receptor blockade unmasks a depressor response to endothelin antagonists in rats.
Richard V; Hogie M; Thuillez C
Fundam Clin Pharmacol; 2000; 14(2):101-6. PubMed ID: 10796056
[TBL] [Abstract][Full Text] [Related]
9. Distinct effects of bosentan on NO-dependent vasodilation and calcium influx in heterozygous Ren-2 transgenic rats on high-salt diet.
Vaněčková I; Hojná S; Kadlecová M; Kompanowska-Jezierska E; Zicha J
Physiol Res; 2019 Oct; 68(5):717-725. PubMed ID: 31424254
[TBL] [Abstract][Full Text] [Related]
10. Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension.
Moreau P; Takase H; Küng CF; Shaw S; Lüscher TF
Hypertension; 1997 Mar; 29(3):763-9. PubMed ID: 9052893
[TBL] [Abstract][Full Text] [Related]
11. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.
Rondelet B; Kerbaul F; Motte S; van Beneden R; Remmelink M; Brimioulle S; McEntee K; Wauthy P; Salmon I; Ketelslegers JM; Naeije R
Circulation; 2003 Mar; 107(9):1329-35. PubMed ID: 12628956
[TBL] [Abstract][Full Text] [Related]
12. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
Krum H; Viskoper RJ; Lacourciere Y; Budde M; Charlon V
N Engl J Med; 1998 Mar; 338(12):784-90. PubMed ID: 9504938
[TBL] [Abstract][Full Text] [Related]
13. Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist.
Zhang Y; Oliver JR; Horowitz JD
Cardiovasc Res; 1998 Sep; 39(3):665-73. PubMed ID: 9861310
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure.
Brochu E; Lacasse S; Larivière R; Kingma I; Grose JH; Lebel M
J Am Soc Nephrol; 1999 Jul; 10(7):1440-6. PubMed ID: 10405199
[TBL] [Abstract][Full Text] [Related]
15. [New expansion of endothelin research: perspectives for clinical application of endothelin-receptor antagonists].
Goto K; Miyauchi T
Nihon Yakurigaku Zasshi; 2003 Feb; 121(2):91-101. PubMed ID: 12616854
[TBL] [Abstract][Full Text] [Related]
16. Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms.
Rossi GP; Sacchetto A; Rizzoni D; Bova S; Porteri E; Mazzocchi G; Belloni AS; Bahcelioglu M; Nussdorfer GG; Pessina AC
Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):949-56. PubMed ID: 10764658
[TBL] [Abstract][Full Text] [Related]
17. The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm.
Shigeno T; Clozel M; Sakai S; Saito A; Goto K
Neurosurgery; 1995 Jul; 37(1):87-90; discussion 90-1. PubMed ID: 8587696
[TBL] [Abstract][Full Text] [Related]
18. Endothelin and heart failure.
Nambi P; Clozel M; Feuerstein G
Heart Fail Rev; 2001 Dec; 6(4):335-40. PubMed ID: 11447308
[TBL] [Abstract][Full Text] [Related]
19. Endothelin receptor blockade improves endothelial function in human internal mammary arteries.
Verma S; Lovren F; Dumont AS; Mather KJ; Maitland A; Kieser TM; Kidd W; McNeill JH; Stewart DJ; Triggle CR; Anderson TJ
Cardiovasc Res; 2001 Jan; 49(1):146-51. PubMed ID: 11121806
[TBL] [Abstract][Full Text] [Related]
20. Endothelin blockade in angiotensin II hypertension: prevention and treatment studies in the rat.
Ficai S; Herizi A; Mimran A; Jover B
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1100-3. PubMed ID: 11903325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
